Integrated Filing — IndAS



General information about company

Scrip Code 539524
NSE Symbol LALPATHLAB
MSEI Symbol NOTLISTED
ISIN INE600L01024
Name of company Dr. Lal Path Labs Ltd.
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 04-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 25-09-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.
Start date and time of board meeting 04-11-2026   11:49:00
End date and time of board meeting 04-11-2026   13:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 30-01-2026
Indicate Company website link for updated RPT policy of the Company https://media.lalpathlabs.com/2026-02/e2734ad1-6dc6-4e03-991d-62ad36076310.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 83,210.00 1,59,650.00
Other income 3,390.00 6,380.00
Total income 86,600.00 1,66,030.00
2 Expenses
(a) Cost of materials consumed 15,360.00 29,790.00
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 12,990.00 25,490.00
(e) Finance costs 690.00 1,300.00
(f) Depreciation, depletion and amortisation expense 4,320.00 8,320.00
(f) Other Expenses
1 Fees to collection centers/channel partners 12,660.00 24,060.00
2 Other expenses 16,490.00 30,750.00
Total other expenses 29,150.00 54,810.00
Total expenses 62,510.00 1,19,710.00
3 Total profit before exceptional items and tax 24,090.00 46,320.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 24,090.00 46,320.00
6 Tax expense
7 Current tax 6,270.00 12,000.00
8 Deferred tax (150.00) (240.00)
9 Total tax expenses 6,120.00 11,760.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 17,970.00 34,560.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 17,970.00 34,560.00
17 Other comprehensive income net of taxes (80.00) 50.00
18 Total Comprehensive Income for the period 17,890.00 34,610.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 16,780.00 16,780.00
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 10.75 20.69
Diluted earnings (loss) per share from continuing operations 10.73 20.64
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 10.75 20.69
Diluted earnings (loss) per share from continuing and discontinued operations 10.73 20.64
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 4 November, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended 30 September, 2026 and they have expressed an unmodified conclusion on the aforesaid results. ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iii. During the quarter and six months ended 30 September 2026, the Company has issued 211,050 and 293,800 equity shares of face value of INR 10 each respectively , to Dr. Lal Pathlabs Employee Welfare Trust under Employee Stock Option Plan, 2022 (ESOP Plan, 2022). iv. The Board of Directors of the Company have approved second interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 4 November, 2026 The Board of Directors of the Company had approved an interim dividend of INR 5 per equity share (face value of INR 10 each) at their meeting held on 24 July, 2026 and this was paid on 11 August, 2026 The Board of Directors of the Company had proposed final dividend of INR 4 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2026. The same was approved by the shareholders in the Annual General Meeting held on 25 July, 2026 and this was paid on 31 July, 2026 v. Acquistions during the half year ended 30 September, 2026 a. During the six months ended 30 September 2026, the Company has acquired 100% Stake in Shahbazkers Diagnostic Centre Private Limited (“SDCPL”) on 1 May, 2026 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of INR 200 million. Pursuant to completion of the aforesaid acquisition, Shahbazkers Diagnostic Centre Private Limited has now become a wholly-owned subsidiary of the Company. SDCPL is primarily engaged in providing diagnostics and healthcare services. b. During the six months ended 30 September 2026, A wholly owned subsidiary, Dr Lal Pathlabs FZCO has been incorporated in Dubai, United Arab Emirates. The Company has subscribed to 19,135 equity shares for AED 1,000 each for a total consideration of AED 19 million. c. During the six months ended 30 September 2026, the Company has made a further investment of INR 77.5 million in its wholly owned subsidiary, Dr. Lal Ventures Private Limited, through subscription of additional equity shares. vi. Subsequent to 30 September 2026, the Parent Company invested an additional INR 303 million in Pathlabs Unifiers Private Limited (PUPL) through subscription to additional equity shares. The funds were utilized by PUPL to acquire the remaining 30% stake in its subsidiary Centrapath Labs Private Limited (CPL) for a consideration of INR 303 million, resulting in CPL becoming a wholly owned subsidiary of PUPL. vii. On 24 September 2026, the Board of Directors of the Company approved the acquisition of a 70% stake in SN Genelab Private Limited (SN Gene) for a cash consideration of up to INR 1,680 million, plus a certain performance-linked earn-out capped at INR 315 million. The transaction was concluded on 1 October 2026, and SN Gene has become a subsidiary of the Company w.e.f 1 October, 2026. SN Gene is primarily engaged in business of providing Diagnostics- Genomics Services. viii. The shareholders of the Company on 7 December, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of INR 10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed 19 December, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on 22 December, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter and Period ended 30 September,2025 have been restated to give effect to the allotment of the bonus shares. ix. On 21 November, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Standalone Statement of Profit and Loss for the year ended 31 March, 2026. x. During the previous year, the Company has regrouped manpower cost aggregating to INR 86 million and INR 166 million respectively for the quarter and half year ended 30 September, 2025, representing collection and transportation charges carried out through third party from employee benefit expenses to other expenses in line with the nature of contract. xi. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. xii. Refer Annexure A for Statement of Standalone Assets and Liabilities and Annexure B for Standalone Cash Flow Statement



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 49,900.00
Capital work-in-progress 450.00
Investment property 3,250.00
Goodwill 47,110.00
Other intangible assets 13,990.00
Intangible assets under development 80.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 19,190.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other financial assets 14,820.00
Total of other non-current financial assets 14,820.00
Total non-current financial assets 34,010.00
Deferred tax assets (net) 8,340.00
Other non-current assets
1 Non-current tax assets (net) 1,180.00
2 Other non-current assets 40.00
Total of other non-current assets 1,220.00
Total non-current assets 1,58,350.00
2 Current assets
Inventories 5,190.00
Current financial asset
Current investments 49,000.00
Trade receivables, current 15,310.00
Cash and cash equivalents 27,910.00
Bank balance other than cash and cash equivalents 70,120.00
Loans, current 210.00
Other current financial assets
Total of other current financial assets 4,720.00
Total current financial assets 1,67,270.00
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,470.00
Total of other current assets 2,470.00
Total current assets 1,74,930.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 3,33,280.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 16,780.00
Other equity 2,52,580.00
Total equity attributable to owners of parent 2,69,360.00
Non controlling interest
Total equity 2,69,360.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 16,990.00
2 Other financial liabilities 410.00
Total of other non-current financial liabilities 17,400.00
Total non-current financial liabilities 17,400.00
Provisions, non-current 0.00
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 17,400.00
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,600.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 16,260.00
Total Trade payable 17,860.00
Other current financial liabilities
1 Lease liabilities 5,700.00
2 Other financial liabilities 8,000.00
Total of other current financial liabilities 13,700.00
Total current financial liabilities 31,560.00
Other current liabilities 3,740.00
1 Other current liabilities 3,740.00
Total of other current liabilities 3,740.00
Provisions, current 8,050.00
Current tax liabilities (Net) 3,170.00
Deferred government grants, Current 0.00
Total current liabilities 46,520.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 63,920.00
Total equity and liabilites 3,33,280.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of the defined benefit obligations (80.00) 90.00
Total Amount of items that will not be reclassified to profit and loss (80.00) 90.00
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 40.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (80.00) 50.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 46,320.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,300.00
Adjustments for decrease (increase) in inventories (1,130.00)
Adjustments for decrease (increase) in trade receivables, current (3,310.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (320.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (130.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 280.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (200.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 8,320.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 960.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (1,120.00)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 160.00
Adjustments for interest income 3,210.00
Adjustments for share-based payments 890.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (680.00)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,490.00
Net cash flows from (used in) operations 47,810.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 9,110.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 38,700.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 7,000.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 30.00
Purchase of property, plant and equipment 3,110.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 60.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 160.00
Interest received 3,920.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (11,640.00)
Net cash flows from (used in) investing activities (17,700.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 1,620.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 1,850.00
Dividends paid 15,030.00
Interest paid 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,270.00)
Net cash flows from (used in) financing activities (16,530.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 4,470.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 4,470.00
Cash and cash equivalents cash flow statement at beginning of period 23,440.00
Cash and cash equivalents cash flow statement at end of period 27,910.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dr. Lal Pathlabs Limited Paliwal Diagnostics Private Limited Subsidairy Sale of goods or services 150.80 NA 150.80 0.00 0.00
2 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Nepal Private Limited Wholly Owned Subsidiary Sale of goods or services 280.40 NA 280.40 1,287.10 1,502.80
3 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Bangladesh Private Limited Subsidairy Sale of goods or services 222.10 NA 222.10 1,741.00 1,963.10
4 Dr. Lal Pathlabs Limited Pathlabs Unifiers Private Limited Wholly Owned Subsidiary Sale of goods or services 20.70 NA 20.70 0.00 0.00
5 Dr. Lal Pathlabs Limited APRL PathLabs Private Limited Subsidairy Sale of goods or services 24.30 NA 24.30 0.00 0.00
6 Dr. Lal Pathlabs Limited Centrapath Labs Private Limited Subsidiary Sale of goods or services 15.00 NA 15.00 0.00 0.00
7 Dr. Lal Pathlabs Limited Dr. Lal Ventures Private Limited Wholly Owned Subsidiary Sale of goods or services 61.60 NA 61.60 0.00 0.00
8 Dr. Lal Pathlabs Limited Chanre Laboratory Private Limited Subsidairy Sale of goods or services 14.40 NA 14.40 0.00 0.00
9 Dr. Lal Pathlabs Limited APRL PathLabs Private Limited Subsidairy Purchase of goods or services 121.00 NA 121.00 0.00 0.00
10 Dr. Lal Pathlabs Limited Centrapath Labs Private Limited Subsidiary Purchase of goods or services 188.70 NA 188.70 0.00 0.00
11 Dr. Lal Pathlabs Limited Chanre Laboratory Private Limited Subsidairy Purchase of goods or services 28.10 NA 28.10 0.00 0.00
12 Dr. Lal Pathlabs Limited Paliwal Diagnostics Private Limited Subsidairy Purchase of goods or services 0.40 NA 0.40 0.00 0.00
13 Dr. Lal Pathlabs Limited Shahbazkers Diagnostic Centre Private Limited Wholly Owned Subsidiary Sale of goods or services 4.00 NA 4.00 0.00 0.00
14 Dr. Lal Pathlabs Limited Sunshine Healthcare Ltd Subsidairy Sale of goods or services 2.90 NA 2.90 0.00 0.00
15 Dr. Lal Pathlabs Limited Neuome Technologies Private Limited Associate Purchase of goods or services 0.10 NA 0.10 0.00 0.00
16 Dr. Lal Pathlabs Limited Dr. Vandana Lal Key Management Personnel and its relatives Remuneration 175.70 NA 175.70 0.00 0.00
17 Dr. Lal Pathlabs Limited (Hony) Brig. Dr. Arvind Lal Key Management Personnel and its relatives Remuneration 219.60 NA 219.60 0.00 0.00
18 Dr. Lal Pathlabs Limited Anjaneya Lal Key Management Personnel and its relatives Remuneration 21.80 NA 21.80 0.00 0.00
19 Dr. Lal Pathlabs Limited Dr. Vandana Lal Key Management Personnel and its relatives Any other transaction Rent 4.30 NA 4.30 0.00 0.00
20 Dr. Lal Pathlabs Limited Dr. Archana Lal Erdmann Key Management Personnel and its relatives/Director Any other transaction Sitting fees and Director Commission 22.10 NA 22.10 0.00 0.00
21 Dr. Lal Pathlabs Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Contribution towards CSR activity 589.20 NA 589.20 0.00 0.00
22 Dr. Lal Pathlabs Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Corpus NA 0.00 1.00 1.00
23 Dr. Lal Pathlabs Limited Dr. Lal PathLabs Limited Group Gratuity Trust Entities with joint control or significant influence over entity Any other transaction Corpus NA 0.00 1.40 1.40
24 Paliwal Diagnostics Private Limited Lal Pathlabs Foundation Entities with joint control or significant influence over entity Any other transaction Contribution towards CSR activity 14.90 NA 14.90 0.00 0.00
25 Dr. Lal Pathlabs Limited Dr. Lal Pathlabs Limited Employee Welfare Trust Entities with joint control or significant influence over entity Any other transaction Issue of equity shares 3,505.40 NA 3,505.40 0.00 0.00
26 Pathlabs Unifiers Private Limited APRL PathLabs Private Limited Subsidairy Purchase of goods or services 1.00 NA 1.00 0.00 0.00
27 APRL PathLabs Private Limited Dr. Subhash Padmani Key Management Personnel and its relatives Remuneration 17.00 NA 17.00 0.00 0.00
28 APRL PathLabs Private Limited Dr. Ripal Padmani Key Management Personnel and its relatives Any other transaction Retainership Fees 7.40 NA 7.40 0.00 0.00
29 Centrapath Labs Private Limited Dr. Vineeta Kothari Key Management Personnel and its relatives Remuneration 15.80 NA 15.80 0.00 0.00
30 Centrapath Labs Private Limited Dr. Vineeta Kothari Key Management Personnel and its relatives Any other transaction Rent NA 3.80 0.00 0.00
31 Chanre Laboratory Private Limited Dr. Renuka Chandrasekhar Key Management Personnel and its relatives Remuneration 24.50 NA 24.50 0.00 0.00
32 Chanre Laboratory Private Limited Dr. Renuka Chandrasekhar Key Management Personnel and its relatives Any other transaction Rent NA 13.80 0.00 0.00
33 Chanre Laboratory Private Limited Chanre Rheumatology and Immunologycenter and Research Private Limited Entities with joint control or significant influence over entity Sale of goods or services 285.80 NA 285.80 39.80 51.40
34 Paliwal Diagnostics Pvt Ltd Dr. Umesh Paliwal Key Management Personnel and its relatives Any other transaction Rent NA 72.10 0.00 0.00
35 Paliwal Diagnostics Pvt Ltd Dr. Umesh Paliwal Key Management Personnel and its relatives Any other transaction Retainership Fees 33.10 NA 33.10 0.00 0.00
36 Paliwal Diagnostics Pvt Ltd Dr. Mridula Paliwal Key Management Personnel and its relatives Any other transaction Retainership Fees 16.50 NA 16.50 0.00 0.00
37 Paliwal Diagnostics Pvt Ltd Mrs. Arushi Paliwal Key Management Personnel and its relatives Any other transaction Rent NA 0.60 0.00 0.00
38 Dr. Lal Pathlabs Limited Dr. Lal Ventures Private Limited Wholly Owned Subsidiary Investment 775.00 NA 775.00 0.00 0.00
39 Dr. Lal PathLabs Bangladesh Private Limited Delower Hossain Key Management Personnel and its relatives Remuneration 19.30 NA 19.30 3.20 2.70
Total value of transaction during the reporting period 6,973.20